Keros Therapeutics, Inc. (KROS) closed the last trading session at $11.59, gaining 5.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Keros Therapeutics, Inc. (KROS) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session.

Kairos Pharma (KAPA) announced that the company presented preclinical data on its investigational compounds KROS 101 and KROS 401 during the ...

NASDAQ KROS opened at $10.56 on Wednesday. The firm has a market capitalization of $427.79 million, a PE ratio of -2.03 and a beta of 1.39. Keros Therapeutics has a 12 month low of $9.77 and a 12 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released on February 28, Jason Zemansky from Bank of America Securities maintained a Buy rating on Keros Therapeutics (KROS – ...

In the presentation, titled “KROS 101: A Next Generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor environment,” study authors demonstrated that KROS ...

Below is a chart showing DKS's trailing twelve month trading history, with the $220 strike highlighted in orange: Keros Therapeutics Inc (Symbol: KROS) options are showing a volume of 10,218 ...